We report here a patient who suffered from PCRconfirmed human herpesvirus type 6 (HHV-6) meningoencephalitis after allogeneic purified CD34
Complications involving the central nervous system (CNS) occur relatively frequently during high-dose therapy and allogeneic hematopoietic stem cell transplantation (HSCT).
1,2 Such complications frequently involve causative agents including drugs such as busulfan, immunosuppressive agents (prednisolone, cyclosporin A), antiviral agents (acyclovir (ACV) and ganciclovir (GCV)), and infectious agents. Intracranial bleeding is another likely CNS complication.
In the field of transplantation, human herpesvirus-6 (HHV-6) has been reported to induce an insignificant skin rash between 14 and 22 days after ordinary bone marrow transplantation (BMT). 3 Rarely reported sequelae of HHV-6 infection include interstitial pneumonitis, 4 ,5 transient marrow suppression, 6 and encephalitis. 7 Although there have been several in vitro studies to suggest that this virus is not sensitive to ACV and only marginally sensitive to GCV, 8 this is currently not supported by any clinical data.
In this report, we describe a patient with severe aplastic anemia (AA) who underwent allogeneic transplantation with purified blood CD34 ϩ cells from his two loci mismatched sibling donor. His course was complicated by meningoencephalitis due to HHV-6, which appeared to be a manifestation of localized reactivation of the virus in the CNS secondary to profound suppression of the immune system. Intense prophylaxis with ACV and ␥-globulin, which contained high titers against the HHV family including herpes simplex (HSV), varicella zoster (VZV), CMV and HHV-6, could not prevent this event. The establishment of prophylaxis and treatment protocol for this virus may be a key factor in expanding this type of transplant.
Case report

History
A 14-year-old boy weighing 38 kg was tentatively diagnosed as having aplastic anemia (AA) by a general practitioner. He was then transferred to our hospital, and the diagnosis of AA was confirmed by examinations including marrow biopsy. Thereafter, he received various treatments including two courses of anti-lymphocyte globulin therapy, intravenous high-dose ␥-globulin, intravenous or oral administration of glucocorticoids, anabolic steroids, and recombinant human granulocyte colony-stimulating factor (G-CSF) with/without recombinant human erythropoietin. However, cytopenia deteriorated to satisfy the criteria of very severe AA and he became transfusion dependent. Since no potential donor was available through the marrow bank, in November 1997 he was selected to undergo transplantation with purified blood CD34 ϩ cells prepared from his two loci mismatched sibling donor (rejection direction one, GVHD direction two). He had an increased risk of viral infection and graft rejection, since he had already received a transfusion of more than 80 units of RBC and 400 units of platelet-rich plasma from the Japanese Red Cross Blood Center. Consequently, 1 month before transplantation, we began prophylactic i.v. treatment with ACV (20 mg/kg/day) for 7 days followed by GCV (15 mg/kg/day) for 14 days.
Transplantation procedure
His 16-year-old brother was enlisted as the donor with a signed consent form approved by the IRB. He received 10 g/kg/day G-CSF (nartograstim; Kyowa-Hakko Kogyo Co., Tokyo, Japan) for 5 consecutive days. On days 5 and 6, large-volume apheresis (20 l each) was performed using a Fenwal CS3000 plus cell separator (Baxter Limited, Tokyo, Japan), and the cells were subjected to CD34 ϩ cell isolation (Isolex 300™, Baxter Healthcare Corp., Deerfield, IL, USA) as reported elsewhere. /kg colony-forming units granulocyte-macrophage (CFU-GM) were isolated. The purified cells were then mixed with an equal volume of freezing medium containing 10% dimethylsulphoxide (DMSO) and 12% hydroxyethylstarch (HES), to which human albumin (Green Cross Co., Kyoto, Japan) was added at a concentration of 12% (v/v). The mixed cell suspension was placed in a deep-freezer maintained at Ϫ135°C (Sanyo Co., Tokyo, Japan) as previously reported. 10 The preparative regimen for transplantation consisted of busulfan (4 mg/kg ϫ 4 days), total lymphoid irradiation (2.5 Gy ϫ 3 days), and cyclophosphamide (60 mg/kg ϫ 2 days). On day 0, the cells were transfused. The T cell dose reinfused was 1.1 ϫ 10 5 /kg of CD3 cells. As GVHD prophylaxis, 3 mg/kg/day of CyA and 1 mg/kg/day methylprednisolone (MPSL) were used. Routine daily prophylaxis with 20 mg/kg/day of ACV (Nippon Wellcome Ltd, Osaka, Japan) and 10 g of ␥-globulin (Polyglobin-N; Bayer Japan, Tokyo, Japan) containing a specific antibody against HHV-6 (titer: 640 ϫ determined by indirect immunofluorescent assay 11 ) once a week was started on day 1.
Clinical course
The early clinical course was uneventful until day 7, when he developed fever up to 38°C. On day 8, he developed a skin rash on his face, trunk and palms, and this was associated with facial swelling. His blood WBC count started to increase on day 10, and this was followed by an increase in the reticulocyte count up to 13‰. At the same time, he suffered from a severe headache, general fatigue, prolonged high-grade fever, and a skin rash on the trunk. After confirming a WBC level of Ͼ20 ϫ 10 9 /l for 3 consecutive days, intravenous MPSL (1 g/day) was administered to overcome the above symptoms on day 16. However, after 3 days of treatment with MPSL, the WBC count abruptly decreased from 2.7 ϫ 10 9 /l to Ͻ0.5 ϫ 10 9 /l with a deteriorating skin rash and continued fever.
On day 20, he developed a severe headache and high blood pressure, which could be controlled with oral medications. Sporadic abnormal neurological findings including nystagmus and delirium were noticed after this episode, and this led to a diagnosis of viral meningoencephalitis, since there were no laboratory data suggestive of bacterial or fungal infection and no signs of intracranial bleeding by a brain CT examination. We then gave him additional doses of ␥-globulin (20 g/2 days) and increased the daily doses of ACV (30 mg/kg/day). After remaining in the same condition, on day 26, he became comatose and an EEG examination showed slow voltage of 5-6 Hz in the occipital area combined with sleep spindle in the frontal area. An analysis of cerebrospinal fluid (CSF) revealed 8 cells/l, a glucose level of 130 mg/dl and a protein level of 201 mg/dl (normal, 50 mg/dl). Culture and direct microscopic examinations of the CSF were all negative for bacteria or fungus. Magnetic resonance imaging of the brain performed the next day showed bilateral dilatation of lateral ventricles and signs of periventriculitis without intracranial bleeding or edema (Figure 1) . Thus, hydrocephalus and periventriculitis due to viral infection were suggested. A drainage catheter was inserted into the right ventricle, and this improved the consciousness level.
Eventually, a molecular viral study was positive for genome DNA of HHV-6, but not for HSV, VZV, Epstein-Barr virus (EBV) or CMV, as examined by Special Reference Laboratory Co (SRL; Tokyo, Japan) using previously reported methods. 12 We failed to find the DNA of HHV-6 in sera or WBC, which transiently increased in the blood of the recipient and transplanted cells from the donor. The titers of IgG against HHV-6 were positive in both the donor's (20ϫ) and the pretransplant recipient's serum (40 ϫ) without an increased IgM level by a retrospective analysis. Thus, reactivation of HHV-6 was suggested. A maximum dose of ACV (60 mg/kg/day) was ineffective and GCV was started, as previously recommended. 8 At the same time, we infused ␣-interferon (3 million units/day; Sumitomo Pharmaceutical Co, Osaka, Japan) three times through the catheter, based on our previous experience. 13 However, we had to discontinue this therapy due to the development of high-grade fever and a worsening consciousness level. HHV-6 was detected in CSF for 3 weeks in three serial CSF samples, and was detected in serum on day 36 (Table 1) . We planned a second transplantation from the same donor after the virus subsided from the CSF. His clinical course was further complicated with meningoencephalitis due to staphylococcus epidermidis on day 52 and he died of tentorial herniation on day 79 without the recovery of blood components. Permission to perform an autopsy was not granted. 
DNA of HHV-6 was repeatedly isolated from CSF of the recipient.
Discussion
Purified CD34 ϩ cell transplantation has become an alternative to ordinary bone marrow transplantation or peripheral blood stem cell transplantation in patients with no HLAidentical donor due to recent progress in purification methods with immunomagnetic beads and anti-CD34 monoclonal antibody. 9 Aversa et al 14 reported that a megadose of purified blood CD34 ϩ cells from a mismatched related donor can overcome an HLA barrier with severe immunosuppressive therapy. Furthermore, transplantation with purified marrow CD34 ϩ cells from haplo-identical related donors has been shown to be useful when combined with severe immunosuppressive therapy. 15 Based on these reports, a severe immunosuppressive conditioning regimen is essential in this setting to avoid graft rejection, although GVHD prophylaxis can be easily achieved by negative T cell depletion.
On the other hand, a high graft rejection rate and an increase in the relapse rate after T cell-depleted transplantation are well-known problems pointed out by previous investigators. 16, 17 Furthermore, the preliminary data of
Bone Marrow Transplantation CD34 ϩ cell transplants suggest the possibility of various types of infections due to such profound immunosuppression. 18, 19 Thus, there seem to be several issues regarding infectious problems that need to be resolved for further expansion of this strategy.
HHV-6 has been shown to invade the CNS system to cause encephalitis or meningoencephalitis, as confirmed by the isolation of viral DNA from the CSF. 20 It is also well known that this virus is reactivated in patients in immunosuppressive conditions and could be a cause of myelosuppression or a factor in the deterioration of acute GVHD in patients with HSCT. In our case, reactivation of HHV-6 could not be avoided with pretransplant treatments including ACV, GCV, and ␥-globulin, or post-transplant prophylactic use of ␥-globulin.
In conclusion, an effective prophylactic protocol for HHV-6 infection or reactivation should be established to further improve treatment strategies that include profound immunosuppression, such as purified CD34 ϩ cell transplant.
